Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802500 | 0.90 | GRIN2D (0.52) | MAOBAKR1B1NR1H4 | |
| SCHEMBL4962122 | 0.86 | MAOB (0.51) | MAOBCYP1A2CYP2C19ALDH1A1LMNA | |
| SCHEMBL13513257 | 0.86 | MAOB (0.51) | MAOBCYP1A2CYP2C19ALDH1A1LMNA | |
| SCHEMBL29674815 | 0.86 | MAOB (0.57) | MAOBAGBL2ALDH1A1LMNAMEN1 | |
| SCHEMBL18844155 | 0.85 | AKR1B1 (0.50) | AKR1B1CYP1A2CYP2C19NR1H4AGBL2 | |
| SCHEMBL29382329 | 0.84 | FOLH1 (0.66) | AKR1B1FOLH1 | |
| SCHEMBL2707508 | 0.84 | FOLH1 (0.66) | AKR1B1FOLH1 | |
| SCHEMBL19202273 | 0.84 | AKR1B1 (0.58) | AKR1B1CYP1A2CYP2C19AGBL2HPSE | |
| SCHEMBL7735116 | 0.83 | MAOB (0.49) | MAOBCYP1A2CYP2C19ALDH1A1LMNA | |
| SCHEMBL4558230 | 0.83 | MAOB (0.49) | MAOBCYP1A2CYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213511-A1 | Calicheamicin Conjugation by Antibody Deglycosylation | WYETH (US) | 2007-09-13 | — | — | US | claimed |
| US-20070190060-A1 | Passive targeting of cytotoxic agents | WYETH (US) | 2007-08-16 | — | — | US | claimed |
| CN-1997398-A | Passive targeting of cytotoxic agents | WYETH CORP (US) | 2007-07-11 | — | — | CN | claimed |
| EP-1725264-A2 | ANTIBODY CALICHEAMICIN CONJUGATES FOR PASSIVE TARGETING | Wyeth (US) | 2006-11-29 | — | — | EP | claimed |
| EP-1725265-A2 | CALICHEAMICIN CONJUGATES BY ANTIBODY DEGLYCOSYLATION | Wyeth (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005089807-A2 | ANTIBODY CALICHEAMICIN CONJUGATES FOR PASSIVE TARGETING | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| WO-2005089809-A2 | CALICHEAMICIN CONJUGATION BY ANTIBODY DEGLYCOSYLATION | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| US-20240374748-A1 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-11-14 | — | — | US | disclosed |
| US-20240307561-A1 | RADIOLABELED PARP INHIBITOR CONJUGATES FOR CANCER TREATMENT | DUKE UNIVERSITY (US) | 2024-09-19 | — | — | US | disclosed |
| EP-3383920-B1 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | UNIV CALIFORNIA (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023278592-A1 | RADIOLABELED PARP INHIBITOR CONJUGATES FOR CANCER TREATMENT | DUKE UNIVERSITY (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20210236650-A1 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | UNIV CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210100838-A1 | HUMAN ANTIBODIES THAT BIND AND ARE INTERNALIZED BY MESOTHELIOMA AND OTHER CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-08 | — | — | US | disclosed |
| WO-2005089809-A3 | CALICHEAMICIN CONJUGATION BY ANTIBODY DEGLYCOSYLATION | WYETH CORP (US) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005089807-A2 | ANTIBODY CALICHEAMICIN CONJUGATES FOR PASSIVE TARGETING | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005089807-A2 | ANTIBODY CALICHEAMICIN CONJUGATES FOR PASSIVE TARGETING | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005089809-A2 | CALICHEAMICIN CONJUGATION BY ANTIBODY DEGLYCOSYLATION | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005089809-A2 | CALICHEAMICIN CONJUGATION BY ANTIBODY DEGLYCOSYLATION | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| EP-1274696-A1 | OXIME DERIVATIVES FOR CONTROLLING UNDESIRED MICROORGANISMS AND ANIMAL PESTS | Bayer CropScience AG (DE) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001072726-A1 | OXIME DERIVATIVES FOR CONTROLLING UNDESIRED MICROORGANISMS AND ANIMAL PESTS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210100838-A1 | HUMAN ANTIBODIES THAT BIND AND ARE INTERNALIZED BY MESOTHELIOMA AND OTHER CANCER CELLS | CD14, EPCAM, CD47 | MAOB 4664/4885AKR1B1 3866/4885CYP1A2 4847/4885 |
| US-20070190060-A1 | Passive targeting of cytotoxic agents | CD22, CD63, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAOB 3083/4885AKR1B1 1515/4885CYP1A2 2828/4885 |
| US-20070213511-A1 | Calicheamicin Conjugation by Antibody Deglycosylation | CD22, ST3GAL3, CD2 | MAOB 2812/4885AKR1B1 3074/4885CYP1A2 3456/4885 |
| US-20240307561-A1 | RADIOLABELED PARP INHIBITOR CONJUGATES FOR CANCER TREATMENT | PARP1, PARP2, PARP3 | MAOB 2412/4885AKR1B1 756/4885CYP1A2 1790/4885 |
| US-20210236650-A1 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | ALPP, HLA-A, ALPI | MAOB 4495/4885AKR1B1 2224/4885CYP1A2 3292/4885 |
| US-20240374748-A1 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | ALPP, HLA-A, ALPI | MAOB 4495/4885AKR1B1 2224/4885CYP1A2 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.